Join Our Network
Pharmacy / Merchant
Copyright © All Samadhan - Operated by M/S. Genius Experts | All Rights Reserved
DBID
Registration ID: 176322642
Trade License: TRAD/DNCC/040904/2023
Copyright © All Samadhan - Operated by M/S. Genius Experts | All Rights Reserved
DBID
Registration ID: 176322642
Trade License: TRAD/DNCC/040904/2023
Popular Pharmaceuticals Ltd. · Ophthalmic Solution
/ 3 ml drop
The information provided on All Samadhan is intended for general informational purposes only and is prepared based on our best practices. It is not a substitute for professional medical advice, diagnosis, or treatment. While we strive to keep the information accurate and up to date, we do not guarantee its completeness or accuracy. The absence of specific information or warnings about any medicine or service should not be considered as an assurance or endorsement by All Samadhan. All Samadhan shall not be held responsible for any consequences arising from the use of this information. We strongly recommend consulting a qualified healthcare professional or physician for any medical concerns, questions, or clarifications.
This is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
This is a fixed-dose combination of a Rho kinase inhibitor and a Prostaglandin F2 analogue. Netarsudil is a Rho kinase inhibitor, works at the cellular level within the trabecular outflow pathway to relax actin-myosin. This causes relaxation within the trabecular meshwork and the inner wall of Schlemm's canal, and decrease episcleral venous pressure (EVP).Latanoprost is a selective FP receptor agonist which reduces the intraocular pressure (IOP) by increasing the outflow of aqueous humor through uveoscleral outflow.
The recommended dosage is one drop in the affected eye(s) once daily in the evening.
The most common ocular adverse reaction observed in controlled clinical studies with Netarsudil & Latanoprost was conjunctival hyperemia, instillation site pain, corneal verticillata, instillation site discomfort, foreign body sensation and blurred visions were reported in few patients.
There are no adequate and well-controlled studies of Netarsudil & Latanoprost combination in pregnant women to inform any drug-associated risk. There are no data on the presence of Netarsudil or Latanoprost in human milk, the effects on the breastfed infant, or the effects on milk production.
For ophthalmic use only
To avoid possible contamination of the drops, do not touch the dropper tip or to any surface
Should be used with caution in patients with active intraocular inflammation (e.g., iritis/uveits)
May cause changes to pigmented tissues, gradually change eyelashes and vellus hair in the treated eye
Cystoid macular edema, has been reported during treatment with Latanoprost. Reactivation of Herpes Simplex keratitis may occur
Netarsudil & Latanoprost combination can be used with other topical eye drug products, but they should be administered at least 5 minutes apart from each other.
Pediatric Use: Safety and effectiveness in pediatric patients have not been established.Use in elderly patients: No overall differences in safety and effectiveness have been observed between elderly and other adult patients.
Drugs for miotics and glaucoma
Store at 2°-8°C in a dry place, protect from light until opened. After opening the product may be kept at 2°-25°C for upto 6 weeks. Keep out of the reach of children.